Development of PPARgamma-activating Nano-Medicine for Cardiovascular Diseases
| Project/Area Number |
25461135
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cardiovascular medicine
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
EGASHIRA Kensuke 九州大学 循環器病未来医療研究センター, 循環器病先端医療研究開発学部門, 教授 (60260379)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | 血管生物学 / ドラッグデリバリーシステム / トランスレーショナルリサーチ / 循環器・高血圧 |
|---|
| Outline of Final Research Achievements |
We carried out translational research projects based on the nanoparticle-mediated drug delivery system and PPAR-gamma agonists to develop a novel Nano-medicine for cardiovascular diseases.
In a mouse model of plaque rupture, PPAR-gamma nano-medicine stabilized atherosclerotic plaques, through a reduction in the number of Ly6C inflammatory monocytes in the peripheral blood and M1 inflammatory macrophage and an increase in M2 macrophage in the aortic tissue.
In a mouse model of myocardial ischemia-reperfusion (IR) injury, PPAR-gamma nano-medicine inhibited monocyte recruitment to IR heart and reduced infarct size.
|
Report
(4 results)
Research Products
(13 results)
